Eltoprazine: Difference between revisions
Importing Wikidata short description: "Chemical compound" |
removed Category:Piperazines; added Category:1-Piperazinyl compounds using HotCat |
||
(2 intermediate revisions by 2 users not shown) | |||
Line 61: | Line 61: | ||
}} |
}} |
||
'''Eltoprazine''' (developmental code name '''DU-28,853''') is a [[serotonergic]] [[drug]] of the [[phenylpiperazine]] class which is described as a [[serenic]] or anti[[aggressive]] agent.<ref name="AdisInsight" /><ref name="pmid2091890">{{cite journal | vauthors = Olivier B, Mos J, Rasmussen D | title = Behavioural pharmacology of the serenic, eltoprazine | journal = Drug Metabol Drug Interact. | volume = 8 | issue = 1–2 | pages = 31–83 | year = 1990 | pmid = 2091890 | doi=10.1515/DMDI.1990.8.1-2.31| s2cid = 27279453 }}</ref><ref name="pmid16310183">{{cite journal | vauthors = de Boer SF, Koolhaas JM | title = 5-HT1A and 5-HT1B receptor agonists and aggression: a pharmacological challenge of the serotonin deficiency hypothesis | journal = Eur J Pharmacol | volume = 526 | issue = 1–3 | pages = 125–39 | date = December 2005 | pmid = 16310183 | doi = 10.1016/j.ejphar.2005.09.065 | url = }}</ref> It acts as an [[agonist]] of the [[serotonin]] [[5-HT1A|5-HT<sub>1A</sub>]] and [[5-HT1B|5-HT<sub>1B</sub> receptor]]s and as an [[antagonist]] of the serotonin [[5-HT2C|5-HT<sub>2C</sub> receptor]].<ref name="pmid16310183" /><ref name="pmid1982626">{{cite journal | vauthors = Schipper J, Tulp MT, Sijbesma H | title = Neurochemical profile of eltoprazine. | journal = Drug Metabol Drug Interact. | volume = 8 | issue = 1–2 | pages = 85–114 | year = 1990 | pmid = 1982626 | doi=10.1515/dmdi.1990.8.1-2.85| s2cid = 30096596 }}</ref> The drug is closely related to [[fluprazine]] and [[batoprazine]], which are similarly acting agents, and is also a known [[precursor (chemistry)|chemical precursor]] to [[S-15535]] and [[lecozotan]]. Eltoprazine is or was under development for the treatment of [[aggression]], [[attention deficit hyperactivity disorder]] (ADHD), [[cognition disorder]]s, and [[drug-induced dyskinesia]], but no recent development has been reported for these indications as of February 2022.<ref name="AdisInsight">{{cite web | url=https://adisinsight.springer.com/drugs/800000719 | title=Eltoprazine - Elto Pharma - AdisInsight }}</ref> It was also under development for the treatment of [[psychotic disorder]]s, but development for this indication was discontinued.<ref name="AdisInsight" /> Eltoprazine was originated by [[Solvay S.A.|Solvay]] and was developed by Elto Pharma, PsychoGenics, and Solvay.<ref name="AdisInsight" /> |
'''Eltoprazine''' (developmental code name '''DU-28,853''') is a [[Serotonin|serotonergic]] [[drug]] of the [[phenylpiperazine]] class which is described as a [[serenic]] or anti[[aggressive]] agent.<ref name="AdisInsight" /><ref name="pmid2091890">{{cite journal | vauthors = Olivier B, Mos J, Rasmussen D | title = Behavioural pharmacology of the serenic, eltoprazine | journal = Drug Metabol Drug Interact. | volume = 8 | issue = 1–2 | pages = 31–83 | year = 1990 | pmid = 2091890 | doi=10.1515/DMDI.1990.8.1-2.31| s2cid = 27279453 }}</ref><ref name="pmid16310183">{{cite journal | vauthors = de Boer SF, Koolhaas JM | title = 5-HT1A and 5-HT1B receptor agonists and aggression: a pharmacological challenge of the serotonin deficiency hypothesis | journal = Eur J Pharmacol | volume = 526 | issue = 1–3 | pages = 125–39 | date = December 2005 | pmid = 16310183 | doi = 10.1016/j.ejphar.2005.09.065 | url = }}</ref> It acts as an [[agonist]] of the [[serotonin]] [[5-HT1A|5-HT<sub>1A</sub>]] and [[5-HT1B|5-HT<sub>1B</sub> receptor]]s and as an [[antagonist]] of the serotonin [[5-HT2C|5-HT<sub>2C</sub> receptor]].<ref name="pmid16310183" /><ref name="pmid1982626">{{cite journal | vauthors = Schipper J, Tulp MT, Sijbesma H | title = Neurochemical profile of eltoprazine. | journal = Drug Metabol Drug Interact. | volume = 8 | issue = 1–2 | pages = 85–114 | year = 1990 | pmid = 1982626 | doi=10.1515/dmdi.1990.8.1-2.85| s2cid = 30096596 }}</ref> The drug is closely related to [[fluprazine]] and [[batoprazine]], which are similarly acting agents, and is also a known [[precursor (chemistry)|chemical precursor]] to [[S-15535]] and [[lecozotan]]. Eltoprazine is or was under development for the treatment of [[aggression]], [[attention deficit hyperactivity disorder]] (ADHD), [[cognition disorder]]s, and [[drug-induced dyskinesia]], but no recent development has been reported for these indications as of February 2022.<ref name="AdisInsight">{{cite web | url=https://adisinsight.springer.com/drugs/800000719 | title=Eltoprazine - Elto Pharma - AdisInsight }}</ref> It was also under development for the treatment of [[psychotic disorder]]s, but development for this indication was discontinued.<ref name="AdisInsight" /> Eltoprazine was originated by [[Solvay S.A.|Solvay]] and was developed by [[Elto Pharma]], [[PsychoGenics]], and Solvay.<ref name="AdisInsight" /> |
||
==References== |
==References== |
||
Line 79: | Line 79: | ||
[[Category:Eltoprazines| ]] |
[[Category:Eltoprazines| ]] |
||
[[Category:Experimental drugs]] |
[[Category:Experimental drugs]] |
||
[[Category: |
[[Category:1-Piperazinyl compounds]] |
||
[[Category:Serotonin receptor agonists]] |
[[Category:Serotonin receptor agonists]] |
Latest revision as of 18:22, 24 July 2023
Clinical data | |
---|---|
Other names | DU-28,853; DU-28853 |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C12H16N2O2 |
Molar mass | 220.272 g·mol−1 |
3D model (JSmol) | |
| |
|
Eltoprazine (developmental code name DU-28,853) is a serotonergic drug of the phenylpiperazine class which is described as a serenic or antiaggressive agent.[1][2][3] It acts as an agonist of the serotonin 5-HT1A and 5-HT1B receptors and as an antagonist of the serotonin 5-HT2C receptor.[3][4] The drug is closely related to fluprazine and batoprazine, which are similarly acting agents, and is also a known chemical precursor to S-15535 and lecozotan. Eltoprazine is or was under development for the treatment of aggression, attention deficit hyperactivity disorder (ADHD), cognition disorders, and drug-induced dyskinesia, but no recent development has been reported for these indications as of February 2022.[1] It was also under development for the treatment of psychotic disorders, but development for this indication was discontinued.[1] Eltoprazine was originated by Solvay and was developed by Elto Pharma, PsychoGenics, and Solvay.[1]
References
[edit]- ^ a b c d "Eltoprazine - Elto Pharma - AdisInsight".
- ^ Olivier B, Mos J, Rasmussen D (1990). "Behavioural pharmacology of the serenic, eltoprazine". Drug Metabol Drug Interact. 8 (1–2): 31–83. doi:10.1515/DMDI.1990.8.1-2.31. PMID 2091890. S2CID 27279453.
- ^ a b de Boer SF, Koolhaas JM (December 2005). "5-HT1A and 5-HT1B receptor agonists and aggression: a pharmacological challenge of the serotonin deficiency hypothesis". Eur J Pharmacol. 526 (1–3): 125–39. doi:10.1016/j.ejphar.2005.09.065. PMID 16310183.
- ^ Schipper J, Tulp MT, Sijbesma H (1990). "Neurochemical profile of eltoprazine". Drug Metabol Drug Interact. 8 (1–2): 85–114. doi:10.1515/dmdi.1990.8.1-2.85. PMID 1982626. S2CID 30096596.
External links
[edit]- Media related to Eltoprazine at Wikimedia Commons
- Eltoprazine - AdisInsight